Clinical characteristics and outcome measures in hidradenitis suppurativa research

2008 ◽  
Vol 15 (6) ◽  
pp. 480-481
Author(s):  
Jean Revuz
Keyword(s):  
Outcome Measures ◽  
Hidradenitis Suppurativa ◽  
Clinical Characteristics

Trends in Hidradenitis Suppurativa Disease Severity and Quality of Life Outcome Measures: A Systematic Review (Preprint)

2021 ◽  
Author(s):  
Jalal Maghfour ◽  
Torunn Elise Sivesind ◽  
Cory A. Dunnick ◽  
Robert Paul Dellavalle
Keyword(s):  
Quality Of Life ◽  
Systematic Review ◽  
Disease Severity ◽  
Outcome Measures ◽  
Hidradenitis Suppurativa ◽  
Life Quality ◽  
Clinical Score ◽  
Validity And Reliability ◽  
Patient Reported

BACKGROUND While there has been an increase in the number of randomized, controlled trials (RCTs) evaluating treatment efficacy for HS, instrument measurements of disease severity and quality of life (QoL) are varied, making compilation of data and comparison between studies a challenge for clinicians. OBJECTIVE The aim of this review is to evaluate trends in disease severity scales and patient reported outcome measures used in RCTs assessing treatment interventions among HS patients. METHODS A primary systematic literature review was conducted in August 2020. PubMed/MEDLINE, Embase, Web of Science, and Cochrane databases were used to identify all articles published from January 1964 to July 2020. The study was prospectively registered with PROSPERO (ID: 209582). Twenty-five articles were included in the systematic review. RESULTS Sartorius and modified Sartorius scores (n=8), and Hidradenitis Suppurativa Clinical score (HiSCs) (n=8) were the most commonly used instruments for disease severity. Participants’ pain, followed by Dermatology Life Quality Index (DLQI), were the most common QoL measures used in the reviewed studies. CONCLUSIONS Heterogeneity of data characterizing both the validity and reliability of existing outcome measures hinders interpretation and translation of the results from RCTs into clinical practice. Many of the QoL measures identified were not specific to HS and may not be representative of all factors impacting patients.

Hidradenitis suppurativa: Clinical characteristics and determinants of treatment efficacy

2019 ◽  
Vol 32 (5) ◽  
Author(s):  
Secil Vural ◽  
Mustafa Gündoğdu ◽  
Bengu N. Akay ◽  
Ayşe Boyvat ◽  
Cengizhan Erdem ◽  
...  
Keyword(s):  
Treatment Efficacy ◽  
Hidradenitis Suppurativa ◽  
Clinical Characteristics

scholarly journals TA Treatment of Emetophobia - A Hermeneutic Single-Case Efficacy Design Study – ‘Peter’

2013 ◽  
Vol 4 (2) ◽  
Author(s):  
Colin Kerr
Keyword(s):  
Outcome Measures ◽  
Strong Evidence ◽  
Clinical Characteristics ◽  
Single Case ◽  
White Male ◽  
Male Student ◽  
Case Record ◽  
Literature Reviews ◽  
The Uk

This study reports on theapplication of Hermeneutic Single Case Efficacy Design (HSCED) (Elliott 2002) to a 39 session TA-based psychotherapy intervention with a 19 year old white male student in the UK who was suffering from emetophobia. The author, who was also the researcher, provides literature reviews on emetophobia clinical characteristics,contrasts it with other phobias, and reviews prior research including TA-based approaches to phobias generally. HSCED Methodology is briefly described; quantitative outcome measures are obtained and analysed using GAD-7 (Spritzer et al 2006)and SPQ (Elliott et al 1999), and qualitative measures via a rich case record, session recordings/transcripts, and a 4-month follow-up interview.  Bohart at al’s (2011) 56 criteria for evidence adjudication were used alongside HSCED criteria. There was strong evidence of significant client changes, and that these changes were the result of the therapy.

scholarly journals Trends in Hidradenitis Suppurativa Disease Severity and Quality of Life Outcome Measures (Preprint)

10.2196/27869 ◽  
2021 ◽  
Author(s):  
Jalal Maghfour ◽  
Torunn Elise Sivesind ◽  
Robert Paul Dellavalle ◽  
Cory Dunnick
Keyword(s):  
Quality Of Life ◽  
Disease Severity ◽  
Outcome Measures ◽  
Hidradenitis Suppurativa

scholarly journals International Dermatology Outcome Measures (IDEOM): Report from the 2020 Annual Meeting

Dermatology ◽  
2021 ◽  
pp. 1-8
Author(s):  
Alison H. Kohn ◽  
Afsaneh Alavi ◽  
April W. Armstrong ◽  
Folawiyo Babalola ◽  
Amit Garg ◽  
...  
Keyword(s):  
Psoriatic Arthritis ◽  
Annual Meeting ◽  
Outcome Measures ◽  
Pyoderma Gangrenosum ◽  
Actinic Keratosis ◽  
Hidradenitis Suppurativa ◽  
Outcome Measurements ◽  
Dermatological Disease ◽  
Patient Reported ◽  
The Impact

<b><i>Background:</i></b> The International Dermatology Outcome Measures (IDEOM) initiative is a non-profit organization that aims to develop evidence-based outcome measurements to evaluate the impact of treatments for patients with dermatological disease. IDEOM includes all key stakeholders in dermatology (patient, physician, industry, insurer, and government) during the process of developing such outcome measurements. <b><i>Summary:</i></b> Here, we provide an update of IDEOM activities that were presented at the 2020 IDEOM Virtual Annual Meeting (October 23–24, 2020). During the meeting, multiple IDEOM workgroups (psoriasis, psoriatic arthritis, hidradenitis suppurativa, acne, pyoderma gangrenosum, and actinic keratosis) shared their progress to date, as well as future directions in developing and validating Patient-Reported Outcome Measures. Updates on demonstrating efficacy in clinicals trials by the US Food and Drug Administration are also summarized. <b><i>Key Messages:</i></b> In this report, we summarize the work presented by each IDEOM workgroup (psoriasis, psoriatic arthritis, hidradenitis suppurativa, acne, pyoderma gangrenosum, and actinic keratosis) at the 2020 IDEOM Virtual Annual Meeting.

Sign in / Sign up

Export Citation Format

Share Document